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Specific receptors for atria1 natriuretic factor were studied in purified glomeruli, proximal tubules, thick as- 
cending limbs of Henle’s loops and collecting ducts from dog kidney. Glomeruli contain the highest concen- 
tration of receptor sites (pK = 9.9, B,,,, = 200 fmol/mg protein), followed by collecting ducts (pK = 9.4, 
B mai = 150 fmol/mg). Low levels of receptor sites were also detectable in thick ascending limbs of Henle’s 
loops (pK = 9.4, B,,, = 36 fmol/mg) while proximal tubules were completely devoid of specific binding 
sites. These results indicate that the glomeruli appear to be the primary site of interaction of artrial natriuret- 
ic factor in kidney cortex but that it might also act in the medulla on lower nephron tubular function. 
Atria1 natriuretic factor Vasoactive peptide Peptide receptor Glomerular function Tubular function 
(Dog kidney) 
1. INTRODUCTION 
Atria1 natriuretic factor (ANF) contained in 
specific granules of atria1 cardiomyocytes [ 1,2] 
seems to be released in response to various 
hemodynamic conditions associated with atria1 
distension or stretch [3-61 by inducing diuresis, 
natriuresis and vasorelaxation [l-7]. Various sites 
of action of ANF have been documented, in- 
cluding arterial muscular tone [8,9], urinary 
sodium and water excretion [ 10,111, adrenal 
mineralocorticoid secretion [ 12,131 and pituitary 
vasopressin secretion [14]. The mode of action of 
ANF on kidney function is still debated [7]. The 
hormone appears to enhance directly the 
glomerular filtration rate and both sodium and 
water filtration fractions [ 15,161. An inhibitory ef- 
fect on tubular reabsorption has also been pro- 
posed [ 16,171. Specific high-affinity receptor sites 
have been documented in aorta [18], adrenal cor- 
tex [19], posterior lobe of the pituitary gland [14] 
and in kidney cortex [ 181. We have documented 
the distribution of ANF receptors in glomeruli and 
tubules purified from dog kidney. The results 
perfectly correlate with a parallel study on ANF- 
induced cGMP production in the same prepara- 
tions [20] as well as with the autoradiographic 
localization of the in vivo uptake of “‘I-ANF in 
rat kidney [21]. 
2. MATERIALS AND METHODS 
2.1. Dog kidney fractionation 
Glomeruli, proximal tubules, thick ascending 
limbs of Henle’s loops and collecting ducts were 
purified from dog kidney as described [22]. Two 
kidneys were excised and rinsed in ice-cold Krebs- 
Henseleit. The cortex, red medulla and white 
medulla were dissected, minced and digested for 
45 min with collagenase in Krebs-Henseleit buffer 
at 37°C. Glomeruli were purified from the cortical 
digest by passing through a 90 pm sieve which re- 
tained the glomeruli. The remaining fraction com- 
pletely devoid of glomeruli was fractionated on a 
Percoll gradient to purify proximal tubules [22]. 
Red and white medulla collagenase digests were 
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similarly fractionated on a Percoll gradient to 
prepare thick ascending limbs of Henle’s loops and 
collecting ducts, respectively. All tissue fractions 
were kept on ice until assayed. 
2.2. ANF receptor assay 
(Arg’“‘-Tyr’26) ANF was iodinated with 
chloramine-T [19] to a specific activity not less 
than 1000 Ci/mmol. Kidney fractions were 
homogenized in ice-cold buffer containing 20 mM 
NaHC03 and 1 mM EDTA in a Teflon-glass 
homogenizer, centrifuged at 40000 x g for 10 min, 
then washed once with buffer and resuspended in 
ice-cold incubation buffer containing 50 mM Tris- 
HCl (pH 7.4) at 25”C, 100 mM NaCl, 5 mM 
MnClz and 0.1 mM EDTA. ANF receptor binding 
was performed by incubating at 25°C for 90 min 
30000 cpm 12’I-ANF (15 fmol) with 25, 50 or 
100 pg membrane protein for glomeruli, collecting 
ducts and Henle’s loops, respectively, in a total 
volume of 1 ml incubation buffer supplemented 
with 0.2% bovine serum albumin and containing 
the indicated concentration of unlabeled ANF. 
The reaction was stopped by dilution with 4 ml ice- 
cold incubation buffer and filtration through 
GF/C glass fiber filters (Whatman) pretreated with 
1% polyethyleneimine. The filters were then im- 
mediately rinsed with 20 ml ice-cold incubation 
buffer and 12’I-ANF trapped on the filters was 
counted in an LKB Quatro gamma counter with an 
efficiency of 80%. Protein was measured using the 
Bradford assay kit (BioRad). 
2.3. Data analysis 
Competition curves were analyzed by nonlinear 
least-squares curve fitting using a model for the 
law of mass action and including provision for 
multiple ligands and classes of binding sites 
together with nonspecific binding [23]. A model in- 
volving 2 classes of binding sites was retained only 
when the resulting goodness of fit was statistically 
significantly better than that for a single class of 
sites. 
3. RESULTS 
Specific high-affinity receptor sites for ANF 
were measured by competitive binding assay using 
rat ‘251-ANF. Purified glomeruli displayed the 
240 
highest level of ANF specific binding. Typical 
competition curves displayed an ICSO for ANF of 
250-300 pmol/l (fig.1). The curves were also flat- 
ter with a slope factor of 0.6-0.7. When these 
curves were analyzed according to models for 1 or 
2 classes of sites, the model for both a high- and 
a low-affinity class of binding sites was statistically 
significantly better @ < 0.01). The class with high 
affinity displayed a pK of 9.9 + 0.3 and a density 
of 205 f 102 fmol/mg protein while the lower af- 
finity component was characterized by a pK of 
8.0 & 0.3 and a larger capacity of 4800 f 
3200 fmol/mg protein (table 1). Following 
removal of all glomeruli by sieving, the collagenase 
digest of kidney cortex provided a source for prox- 
imal tubules. That preparation was completely 
devoid of receptor sites for “‘1-ANF and absolute- 
ly no specific binding could be documented above 
nonspecific binding level (850 cpm/tube). These 
results indicate that all high-affinity binding sites 
in dog kidney cortex are located in glomeruli. Fig. 1 
also shows that specific binding sites for ANF were 
also present in the medulla, especially in collecting 
ducts obtained from white medulla (148 -t 
43 fmol/mg protein), and to a smaller extent in 
thick ascending limbs of Henle’s loops prepared 
from red medulla (36 +- 8 fmol/mg protein). Only 
high-affinity binding sites could be documented in 
these 2 preparations with pK of 9.4 (table 1). 
Table 1 
Distribution of ANF binding sites in dog kidney 
fractions 
Fraction R” (fmol/mg 
protein) 
Glomeruli (n = 4)b 9.9 f 0.3’ 205 + 102 
8.0 + 0.3 4800 + 3200 
Proximal tubules (n = 3) 
Thick ascending Henle’s 
_ Od 
loops (n = 3) 9.4 + 0.1 36r+_ 8 
Collecting ducts (n = 7) 9.4 f 0.2 148 + 43 
a pK, loglo of equilibrium constant (reciprocal of 
dissociation constant); R, total binding capacity 
b Number of experiments 
‘ Mean rt SE 
d No specific binding above nonspecific level 
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Fig.1. Competitive binding curves for ANF in dog 
kidney fractions. ‘?-ANF (15 PM) was incubated at 
25°C for 90 min with varying concentrations of 
unlabeled ANF and 26, 44 and 97 pg protein/ml of 
membranes from glomeruli, collecting ducts or Henle’s 
loops, respectively. Membrane-bound lz51-ANF was 
separated by filtration and washing on GF/C glass fiber 
filters. 
4. DISCUSSION 
These results confirm and extend a previous 
report by Napier et al. [ 181 of specific receptor sites 
for ANF in kidney cortex as well as in a porcine 
kidney tumor cell line of medullary origin. The 
localization of ANF binding sites also perfectly 
correlates with that for ANF-induced cGMP pro- 
duction reported by Tremblay et al. [20] in a 
parallel study. Interestingly, ANF-sensitive par- 
ticulate guanylate cyclase has been documented in 
all target organs also containing ANF receptor 
binding sites, strongly suggesting a close associa- 
tion of ANF receptor with guanylate cyclase in the 
plasma membrane of target cells. The localization 
within kidney cortex of ANF binding sites only in 
the glomeruli was also observed by Bianchi et al. 
[21]. These results strongly suggest that the 
glomeruli and not the proximal tubules constitute 
the primary site of interaction of ANF in kidney 
cortex. Micropuncture studies of the effect of ANF 
on kidney function have also documented a 
primary influence of glomerular filtration rate 
with a secondary increase in water and sodium ex- 
cretion rate [15]. The same studies could not 
however preclude changes in medullary blood flow 
distribution or in ion transport by lower nephron 
segments [ 151. The observation of specific receptor 
sites in ascending limbs of Henle’s loops and 
especially in collecting ducts suggests that ANF 
might also modulate ion and water transport. The 
presence of a low level of ANF uptake in vasa recta 
documented by Bianchi et al. [21] could not be 
confirmed in these studies because vascular struc- 
tures were not recovered in the collagenase digests. 
The localization of ANF binding sites in the 
kidney strikingly correlates with that for 
vasopressin [24]. Vasopressin receptors not cou- 
pled with adenylate cyclase activation have been 
identified in glomeruli and appear to correspond to 
the same Vl subclass also found in vascular 
smooth muscle [24]. V2 subtype receptors are 
localized to Henle’s loops and collecting ducts and 
are positively coupled to adenylate cyclase [24]. It 
is not yet known whether glomerular and collecting 
duct receptors for ANF might correspond to 
distinct subtypes. Further characterization of ANF 
receptor components in these various kidney frac- 
tions will help to ascertain their similarity as well 
as their mechanism of action. 
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